OrbiMed Launches $924 Million Royalty & Credit Opportunities Fund

NEW YORK--(BUSINESS WIRE)--OrbiMed, a leading investment firm focused on the healthcare sector, today announced the closing of its second healthcare royalty and credit opportunities Fund, OrbiMed Royalty Opportunities II, LP, with $924 million in commitments, including $24 million from the General Partner. Investors in the fund include a broad range of premier endowment, foundation, pension and other institutional investors.

“OrbiMed is active across a broad range of worldwide healthcare investing, including royalty and credit opportunities, public equity, and private equity. Interest in this fund reflects the strong appeal of the OrbiMed strategy and our $14 billion global platform”

Consistent with its predecessor, the new fund will acquire healthcare royalty streams and provide tailored debt capital solutions to healthcare companies and institutions worldwide. The Fund expects to commit between $20 million to $150 million per investment, with the ability to commit larger amounts in collaboration with other OrbiMed funds.

“OrbiMed is active across a broad range of worldwide healthcare investing, including royalty and credit opportunities, public equity, and private equity. Interest in this fund reflects the strong appeal of the OrbiMed strategy and our $14 billion global platform,” said Samuel D. Isaly, Managing Partner.

“We are grateful for strong support from the LP community, which made for an efficient fundraise that exceeded our target with just a single closing,” said W. Carter Neild, a Partner at OrbiMed. “We are particularly excited to welcome a dozen leading medical research and healthcare institutions as investors. OrbiMed looks forward to a strategic, collaborative relationship with them going forward.”

"We offer structured capital solutions, including combinations of royalty, debt, and equity financing, that provide companies and institutions another tool to solve their capital needs while also bringing them into the OrbiMed family," noted Tadd Wessel, a Managing Director at OrbiMed.

“We are a value-added partner for our portfolio companies, bringing OrbiMed’s substantial strategic and operational resources to help them grow successfully,” commented Matthew Rizzo, a Managing Director at OrbiMed.

About OrbiMed

OrbiMed is a leading investment firm dedicated exclusively to the healthcare sector, with over $14 billion in assets under management. OrbiMed invests globally across the spectrum of healthcare companies, from venture capital start-ups to large multinational companies utilizing a range of private equity funds, public equity funds, royalty/debt funds and other investment vehicles. OrbiMed maintains its headquarters in New York City, with additional offices in San Francisco, Shanghai, Mumbai and Herzliya.

OrbiMed seeks to be a capital provider of choice, with the flexibility to provide equity and debt capital solutions that are tailored to the unique needs of our portfolio companies. The firm’s global team of over 80 professionals brings the resources and experience required to be an exceptional long-term partner in building world-class healthcare companies. www.OrbiMed.com.